Synthesis 2012; 44(21): 3307-3314
DOI: 10.1055/s-0032-1316779
paper
© Georg Thieme Verlag Stuttgart · New York

Asymmetric [3+2] Cycloaddition of Azomethine Ylides Catalyzed by Silver(I) Triflate with a Chiral Bipyrrolidine-Derived Phosphine Ligand

Xin Gu
a   Shanghai-Hong Kong Joint Laboratory in Chemical Synthesis, Shanghai Institute of Organic Chemistry, 345 Lingling Road, Shanghai 200032, P. R. of China   Fax: +86(21)64166128   Email: xuzhenjiang@mail.sioc.ac.cn
,
Zhen-Jiang Xu*
a   Shanghai-Hong Kong Joint Laboratory in Chemical Synthesis, Shanghai Institute of Organic Chemistry, 345 Lingling Road, Shanghai 200032, P. R. of China   Fax: +86(21)64166128   Email: xuzhenjiang@mail.sioc.ac.cn
,
Vanessa Kar-Yan Lo
b   Department of Chemistry, State Key Laboratory of Synthetic Chemistry and Open Laboratory of Chemical Biology of the Institute of Molecular Technology for Drug Discovery and Synthesis, The University of Hong Kong, Pokfulam Road, Hong Kong, P. R. of China   Fax: +852(2857)1586   Email: cmche@hku.hk
,
Chi-Ming Che*
a   Shanghai-Hong Kong Joint Laboratory in Chemical Synthesis, Shanghai Institute of Organic Chemistry, 345 Lingling Road, Shanghai 200032, P. R. of China   Fax: +86(21)64166128   Email: xuzhenjiang@mail.sioc.ac.cn
b   Department of Chemistry, State Key Laboratory of Synthetic Chemistry and Open Laboratory of Chemical Biology of the Institute of Molecular Technology for Drug Discovery and Synthesis, The University of Hong Kong, Pokfulam Road, Hong Kong, P. R. of China   Fax: +852(2857)1586   Email: cmche@hku.hk
› Author Affiliations
Further Information

Publication History

Received: 26 June 2012

Accepted after revision: 30 August 2012

Publication Date:
14 September 2012 (online)


Abstract

Two novel chiral bipyrrolidine-derived phosphine ligands L1 and L2 were synthesized. The ‘AgOTf + L1’ protocol catalyzes the asymmetric [3+2] cycloaddition of azomethine ylides with alkenes to give highly substituted pyrrolidines in good yields (up to 90%) with moderate to high diastereoselectivities (up to >19:1 dr) and enantioselectivities (up to 76%).

Supporting Information